<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405402</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-PRO-TRANSFU-DREPANO 1</org_study_id>
    <nct_id>NCT03405402</nct_id>
  </id_info>
  <brief_title>Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization</brief_title>
  <official_title>Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanane EL KENZ</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell patients have a high prevalence of alloimmunization. This high rate of
      alloimmunization can be partially explained by the existence of an antigenic difference
      between the predominantly Caucasian donor population and the sickle cell patients of African
      origin. Genetic and environmental risk factors have also been described.

      The main risk factors that have been shown in retrospective or cross-sectional studies are
      some HLA alleles, the age of the patient, the number of leukocyte-depleted erythrocyte
      concentrates (CED) transfused, the number of transfusion episodes, the age of the CEDs, the
      existence of an inflammatory event at the time of transfusion and the presence of
      anti-erythrocyte autoantibodies.There is also evidence of an impaired TH response but the
      underlying immunological mechanism is not fully understood.

      The aim of this study is to study the prevalence and the risk factors for anti-erythrocyte
      alloimmunization and to try to understand the immunological mechanisms.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Irregular antibodies</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Presence/abscence of irregular antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Irregular antibodies</measure>
    <time_frame>Between 2 to 4 weeks after blood transfusion</time_frame>
    <description>Presence/abscence of irregular antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>CRP dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Cytokine dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine</measure>
    <time_frame>Between 2 to 4 weeks after blood transfusion</time_frame>
    <description>Cytokine dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heme oxygenase</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Heme oxygenase dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heme oxygenase</measure>
    <time_frame>Between 2 to 4 weeks after blood transfusion</time_frame>
    <description>Heme oxygenase dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphocyte typing</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Lymphocyte typing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphocyte typing</measure>
    <time_frame>Between 2 to 4 weeks after blood transfusion</time_frame>
    <description>Lymphocyte typing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sex</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic or acute blood transfusion</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Blood transfusions planned at regular intervals of time (chronic transfusions) or performed in reaction to a medical issue (acute transfusion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion indication</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Medical reason explaining the necessity of a blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood donor ethnicity</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Blood donor ethnicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allo-immunization detected (positive response for irregular antibodies 2 to 4 weeks after a blood transfusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Allo-immunization not detected</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Sickle cell disease patients treated within the CHU Brugmann or Queen Fabiola Children's
        Hospital

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Deleers, Ph Biol</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Deleers, Ph Biol</last_name>
    <phone>32 2 477 24 09</phone>
    <email>marie.deleers@chu-brugmann.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanane El Kenz, Ph Biol</last_name>
    <phone>+ 32 2 477 27 34</phone>
    <email>hanene.elkenz@chu-brugmann.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUDERF</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Hanane EL KENZ</investigator_full_name>
    <investigator_title>Head of Blood Bank</investigator_title>
  </responsible_party>
  <keyword>Sickle cell disease</keyword>
  <keyword>Allo-immunization</keyword>
  <keyword>Blood transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

